Generative AI Patient Education Module for Breast Oncology

March 30, 2026 updated by: University of California, San Francisco

Accuracy and Effect of Prescribed Generative AI Patient Education Module Within Breast Oncology Care

This study evaluates the safety, accuracy, and impact of an artificial intelligence (AI) tool designed to support patient education in breast cancer care for breast oncology patients under selected physicians care within the University of California, San Francisco breast cancer center and affiliate sites.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

PRIMARY OBJECTIVES:

I. Lead-in period: To evaluate the safety of the OpenEvidence CareConnect a Retrieval-Augmented Generation (RAG) Large Language Model (LLM) tool during the initial lead-in phase in patients with metastatic breast cancer.

II. To evaluate the clinical accuracy and appropriateness of the OpenEvidence CareConnect RAG LLM tool in delivering general health and breast cancer-specific information.

SECONDARY OBJECTIVES:

I. To assess patient perceptions of the AI tool's helpfulness, alignment with other information sources, and its impact on communication with their oncology care team.

II. To evaluate provider perceptions of the tool's usefulness and impact on communication and the quality of patient education.

III. To compare patient experiences and perceptions between immediate access and delayed access to the AI educational tool.

EXPLORATORY OBJECTIVES:

I. To evaluate the changes in inter-visit communication between patient and care team with and without access to the AI tool.

II. To understand patient concerns and educational needs related to breast cancer diagnosis and treatment.

OUTLINE: The first 5 participants will be assigned to the Lead-In Phase. After which, the next 30 participants will be randomized to either an Intervention arm or a Waitlist Control arm. Participants on the Waitlist Control arm will cross over after 3 months to the Intervention arm. Surveys and provider assessments occur throughout, and adherence and safety are monitored during the lead-in. Each participant will be on study for approximately 6 months.

Study Type

Interventional

Enrollment (Estimated)

35

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • United States
    • California
      • San Francisco, California, United States, 94143
        • University of California, San Francisco
        • Contact:
        • Contact:
        • Principal Investigator:
          • Michelle Melisko, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Females or males ages 18 and over.

  2. Patients must have either:

    1. Stage IV breast cancer facing a treatment change and are expected to have follow-up visits at least once every three months, or
    2. Stage I-III breast cancer diagnosed within the past 6 months.
  3. Basic computer literacy and regular internet access at home.
  4. Able to understand study procedures and to comply with them for the entire length of the study.
  5. Ability of individual or legal guardian/representative to understand a written informed consent document, and the willingness to sign it.

Exclusion Criteria:

  1. Contraindication to any study-related procedure or assessment.
  2. Cognitive impairment that would interfere with tool usage or survey completion

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Safety Lead-in Phase
Participants will receive access to OpenEvidence CareConnect a Retrieval-Augmented Generation (RAG) Large Language Model (LLM) tool that provides general health and breast cancer-specific information for 3 months.
Other: Survey (Participant)
Participants will complete surveys to evaluate their experience using OpenEvidence CareConnect RAG LLM tool.
Other: OpenEvidence CareConnect
Retrieval-Augmented Generation (RAG) Large Language Model (LLM) tool
Other: Survey (Provider)
The provider will complete a survey to assess OpenEvidence CareConnect RAG LLM tool's usefulness and the quality of its patient education communication.
Experimental: Interventional (Immediate Access)
Participants will be given immediate access to OpenEvidence CareConnect for up to 3 months and complete surveys regarding use of tool. Participants are then followed up for an additional 3 months.
Other: Survey (Participant)
Participants will complete surveys to evaluate their experience using OpenEvidence CareConnect RAG LLM tool.
Other: OpenEvidence CareConnect
Retrieval-Augmented Generation (RAG) Large Language Model (LLM) tool
Other: Survey (Provider)
The provider will complete a survey to assess OpenEvidence CareConnect RAG LLM tool's usefulness and the quality of its patient education communication.
Experimental: Control (Delayed Access)
Participants will be given access to OpenEvidence CareConnect for 3 months 90 days after enrollment
Other: Survey (Participant)
Participants will complete surveys to evaluate their experience using OpenEvidence CareConnect RAG LLM tool.
Other: OpenEvidence CareConnect
Retrieval-Augmented Generation (RAG) Large Language Model (LLM) tool
Other: Survey (Provider)
The provider will complete a survey to assess OpenEvidence CareConnect RAG LLM tool's usefulness and the quality of its patient education communication.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mean score of Safety and Risk Assessment (Lead-in and Provider)
Time Frame: Up to 90 months
Safety and Risk Assessment evaluates safety concerns based on provider responses using a 5-point Likert scale.
Up to 90 months
Mean score of Provider Assessment of AI patient Education Tool Survey (Provider)
Time Frame: Up to 180 days
AI patient Education Tool Survey evaluates clinical accuracy and appropriateness of the OpenEvidence CareConnect tool based on provider responses using a 5-point Likert scale ranging from 1 (Strongly Disagree) to 5 (Strongly Agree).
Up to 180 days
Mean score of Assessment of Answer Accuracy and Content Appropriateness (Provider)
Time Frame: Uup to 180 days
Provider will evaluate participant questions, answer accuracy and content provided within the OpenEvidence using 3-point scales.
Uup to 180 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mean score of AI Tool Experience survey (Participant)
Time Frame: Up to 180 days
The AI Tool Experience Survey is a 40-question instrument to assess participants' perceptions of usability, usefulness, clinical integration, and support for shared decision-making. Each item is rated on a 5-point Likert scale ranging from 1 (Strongly Disagree) to 5 (Strongly Agree).
Up to 180 days
Mean score of Medical Information Experience Survey (Participant)
Time Frame: up to 180 days
Medical Information Experience Survey is a 13-question instrument to evaluate how participants access and engage with medical information. Questions are measured using a 5-point Likert scale.
up to 180 days
Mean Change of Score of Patient AI Tool Experience Survey (Participant)
Time Frame: up to 180 days
The AI Tool Experience Survey is a 40-question instrument to assess participants' perceptions of usability, usefulness, clinical integration, and support for shared decision-making. Each item is rated on a 5-point Likert scale ranging from 1 (Strongly Disagree) to 5 (Strongly Agree). Comparisons of survey responses between the immediate and delayed access groups will be reported.
up to 180 days
Mean Change of Score of Medical Information Experience Survey (Participant)
Time Frame: Up to 180 days
Medical Information Experience Survey is a 13-question instrument evaluates how participants access and engage with medical information. Questions are measured using a 5-point Likert scale. Comparisons of survey responses between the immediate and delayed access groups will be reported.
Up to 180 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of California, San Francisco

Investigators

  • Principal Investigator: Michelle Melisko, MD, University of California, San Francisco

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

May 1, 2026

Primary Completion (Estimated)

December 31, 2026

Study Completion (Estimated)

December 31, 2026

Study Registration Dates

First Submitted

March 30, 2026

First Submitted That Met QC Criteria

March 30, 2026

First Posted (Actual)

April 6, 2026

Study Record Updates

Last Update Posted (Actual)

April 6, 2026

Last Update Submitted That Met QC Criteria

March 30, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 257517
  • NCI-2026-02050 (Registry Identifier: NCI Trial ID)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Breast Cancer

Clinical Trials on Survey (Participant)

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malawi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe